Skip to main content
NCBI home page
The Yale Journal of Biology and Medicine logoLink to The Yale Journal of Biology and Medicine
. 1982 May-Aug;55(3-4):375–381.

Hepatitis virus vaccines: present status.

S Krugman
PMCID: PMC2596435  PMID: 6295013

Abstract

During the past decade there has been extraordinary progress toward the development of vaccines for the prevention of type A and type B hepatitis. The successful propagation of hepatitis A virus in cell culture in 1979 was followed by the preparation of experimental live attenuated hepatitis A vaccines that have been shown to induce antibody in marmosets and chimpanzees and protect immunized marmosets against challenge with hepatitis A virus. The first human immunization trials will begin in mid-1982. An inactivated hepatitis B vaccine that was licensed in the United States in November 1981 has been shown to be safe, immunogenic, and effective. When this vaccine becomes available for use in July 1982, it will be recommended for persons who are considered to be at increased risk of contracting hepatitis B infection. Future generations of hepatitis B vaccines may be prepared from hepatitis B surface antigen derived from DNA recombinant technology or by in vitro synthesis of HBs Ag determinants by chemical means.

Full text

PDF
375

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BLUMBERG B. S., ALTER H. J., VISNICH S. A "NEW" ANTIGEN IN LEUKEMIA SERA. JAMA. 1965 Feb 15;191:541–546. doi: 10.1001/jama.1965.03080070025007. [DOI] [PubMed] [Google Scholar]
  2. Barin F., Goudeau A., Denis F., Yvonnet B., Chiron J. P., Coursaget P., Mar I. D. Immune response in neonates to hepatitis B vaccine. Lancet. 1982 Jan 30;1(8266):251–253. doi: 10.1016/s0140-6736(82)90977-1. [DOI] [PubMed] [Google Scholar]
  3. Barker L. F., Chisari F. V., McGrath P. P., Dalgard D. W., Kirschstein R. L., Almeida J. D., Edington T. S., Sharp D. G., Peterson M. R. Transmission of type B viral hepatitis to chimpanzees. J Infect Dis. 1973 Jun;127(6):648–662. doi: 10.1093/infdis/127.6.648. [DOI] [PubMed] [Google Scholar]
  4. Deinhardt F., Holmes A. W., Capps R. B., Popper H. Studies on the transmission of human viral hepatitis to marmoset monkeys. I. Transmission of disease, serial passages, and description of liver lesions. J Exp Med. 1967 Apr 1;125(4):673–688. doi: 10.1084/jem.125.4.673. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Enders J. F., Weller T. H., Robbins F. C. Cultivation of the Lansing Strain of Poliomyelitis Virus in Cultures of Various Human Embryonic Tissues. Science. 1949 Jan 28;109(2822):85–87. doi: 10.1126/science.109.2822.85. [DOI] [PubMed] [Google Scholar]
  6. Feinstone S. M., Kapikian A. Z., Purceli R. H. Hepatitis A: detection by immune electron microscopy of a viruslike antigen associated with acute illness. Science. 1973 Dec 7;182(4116):1026–1028. doi: 10.1126/science.182.4116.1026. [DOI] [PubMed] [Google Scholar]
  7. Frösner G. G., Deinhardt F., Scheid R., Gauss-Müller V., Holmes N., Messelberger V., Siegl G., Alexander J. J. Propagation of human hepatitis A virus in a hepatoma cell line. Infection. 1979;7(6):303–305. doi: 10.1007/BF01642154. [DOI] [PubMed] [Google Scholar]
  8. Hilleman M. R., Buynak E. B., Roehm R. R., Tytell A. A., Bertland A. U., Lampson G. P. Purified and inactivated human hepatitis B vaccine: progress report. Am J Med Sci. 1975 Sep-Oct;270(2):401–404. doi: 10.1097/00000441-197509000-00025. [DOI] [PubMed] [Google Scholar]
  9. Krugman S., Giles J. P., Hammond J. Viral hepatitis, type B (MS-2 strain). Studies on active immunization. JAMA. 1971 Jul 5;217(1):41–45. [PubMed] [Google Scholar]
  10. Krugman S., Holley H. P., Jr, Davidson M., Simberkoff M. S., Matsaniotis N. Immunogenic effect of inactivated hepatitis B vaccine: comparison of 20 microgram and 40 microgram doses. J Med Virol. 1981;8(2):119–121. doi: 10.1002/jmv.1890080205. [DOI] [PubMed] [Google Scholar]
  11. Krugman S. The newly licensed hepatitis B vaccine. Characteristics and indications for use. JAMA. 1982 Apr 9;247(14):2012–2015. [PubMed] [Google Scholar]
  12. Mascoli C. C., Ittensohn O. L., Villarejos V. M., Arguedas J. A., Provost P. J., Hilleman M. R. Recovery of hepatitis agents in the marmoset from human cases occurring in Costa Rica. Proc Soc Exp Biol Med. 1973 Jan;142(1):276–282. doi: 10.3181/00379727-142-37005. [DOI] [PubMed] [Google Scholar]
  13. Maupas P., Chiron J. P., Barin F., Coursaget P., Goudeau A., Perrin J., Denis F., Mar I. D. Efficacy of hepatitis B vaccine in prevention of early HBsAg carrier state in children. Controlled trial in an endemic area (Senegal). Lancet. 1981 Feb 7;1(8215):289–292. doi: 10.1016/s0140-6736(81)91908-5. [DOI] [PubMed] [Google Scholar]
  14. Maupas P., Goudeau A., Coursaget P., Drucker J., Bagros P. Immunisation against hepatitis B in man. Lancet. 1976 Jun 26;1(7974):1367–1370. doi: 10.1016/s0140-6736(76)93023-3. [DOI] [PubMed] [Google Scholar]
  15. Prince A. M. An antigen detected in the blood during the incubation period of serum hepatitis. Proc Natl Acad Sci U S A. 1968 Jul;60(3):814–821. doi: 10.1073/pnas.60.3.814. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Provost P. J., Hilleman M. R. An inactivated hepatitis A virus vaccine prepared from infected marmoset liver. Proc Soc Exp Biol Med. 1978 Nov;159(2):201–203. doi: 10.3181/00379727-159-40314. [DOI] [PubMed] [Google Scholar]
  17. Provost P. J., Wolanski B. S., Miller W. J., Ittensohn O. L., McAleer W. J., Hilleman M. R. Physical, chemical and morphologic dimensions of human hepatitis A virus strain CR326 (38578). Proc Soc Exp Biol Med. 1975 Feb;148(2):532–539. doi: 10.3181/00379727-148-38578. [DOI] [PubMed] [Google Scholar]
  18. Purcell R. H., Gerin J. L. Hepatitis B subunit vaccine: a preliminary report of safety and efficacy tests in chimpanzees. Am J Med Sci. 1975 Sep-Oct;270(2):395–399. [PubMed] [Google Scholar]
  19. Siegl G., Frösner G. G. Characterization and classification of virus particles associated with hepatitis A. II. Type and configuration of nucleic acid. J Virol. 1978 Apr;26(1):48–53. doi: 10.1128/jvi.26.1.48-53.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Szmuness W., Stevens C. E., Harley E. J., Zang E. A., Oleszko W. R., William D. C., Sadovsky R., Morrison J. M., Kellner A. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med. 1980 Oct 9;303(15):833–841. doi: 10.1056/NEJM198010093031501. [DOI] [PubMed] [Google Scholar]
  21. Szmuness W., Stevens C. E., Harley E. J., Zang E. A., Taylor P. E., Alter H. J. The immune response of healthy adults to a reduced dose of hepatitis B vaccine. J Med Virol. 1981;8(2):123–129. doi: 10.1002/jmv.1890080206. [DOI] [PubMed] [Google Scholar]
  22. Szmuness W., Stevens C. E., Oleszko W. R., Goodman A. Passive-active immunisation against hepatitis B: immunogenicity studies in adult Americans. Lancet. 1981 Mar 14;1(8220 Pt 1):575–577. doi: 10.1016/s0140-6736(81)92030-4. [DOI] [PubMed] [Google Scholar]
  23. Szmuness W., Stevens C. E., Zang E. A., Harley E. J., Kellner A. A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report. Hepatology. 1981 Sep-Oct;1(5):377–385. doi: 10.1002/hep.1840010502. [DOI] [PubMed] [Google Scholar]
  24. Tao C. M., Huang T. Y., Feng P. F., Wu C. H., Liu Y. C., Li H. F., Wang C. C. A preliminary study on hepatitis B vaccine. Chin Med J (Engl) 1978 Mar;4(2):101–110. [PubMed] [Google Scholar]

Articles from The Yale Journal of Biology and Medicine are provided here courtesy of Yale Journal of Biology and Medicine

RESOURCES